<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Dermatologic</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Recludix presents STAT1/3 inhibitors for dermatological diseases</title>
      <description>
        <![CDATA[Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731235</guid>
      <pubDate>Thu, 21 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731235-recludix-presents-stat1-3-inhibitors-for-dermatological-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-atopic-dermatitis2.webp?t=1588881560" type="image/png" medium="image" fileSize="357317">
        <media:title type="plain">Skin irritation on hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Genescience presents STAT6 degrader for atopic dermatitis</title>
      <description>
        <![CDATA[Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation. GenSciP166 was assayed in vitro as well as in vivo in the MC903 atopic dermatitis murine model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731177</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731177-genescience-presents-stat6-degrader-for-atopic-dermatitis</link>
    </item>
    <item>
      <title>Biocryst’s BCX-17725 as new approach for Netherton syndrome</title>
      <description>
        <![CDATA[Netherton syndrome is a rare disease caused by loss of activity of the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein, which in turn is caused by mutations in its encoding gene, SPINK5. This deficiency leads to the triggering of the kallikrein (KLK) signaling cascade resulting in skin barrier dysfunction, inflammation and atopy. At the recent Society for Investigative Dermatology meeting, Biocryst Pharmaceuticals Inc. presented early data on BCX-17725, a KLK5/KLK14 inhibitor fusion protein developed to restore LEKTI functioning in patients with Netherton syndrome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731160</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731160-biocrysts-bcx-17725-as-new-approach-for-netherton-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-anatomy-and-DNA.webp?t=1777580724" type="image/jpeg" medium="image" fileSize="187452">
        <media:title type="plain">Skin anatomy and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis </title>
      <description>
        <![CDATA[Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of atopic dermatitis (AD). Targeting STAT6, the key downstream mediator, offers a more selective strategy that could reproduce biologic efficacy while reducing off-target effects.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731157</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731157-recludixs-first-in-class-stat6-inhibitor-shows-efficacy-in-atopic-dermatitis</link>
    </item>
    <item>
      <title>First measles treatment advances as vaccination rates drop</title>
      <description>
        <![CDATA[Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry into the cell. This is the first time that antibodies have been shown to bind effectively to two essential viral proteins, creating a dual blockade that prevents infection. Unlike the current vaccine, which is based on an attenuated virus and is not recommended for immunocompromised individuals, these monoclonal antibodies could be used both as a new vaccine approach and as a treatment for the entire population.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730929</guid>
      <pubDate>Thu, 07 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730929-first-measles-treatment-advances-as-vaccination-rates-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/F_Fab1.webp?t=1778167596" type="image/png" medium="image" fileSize="120510">
        <media:title type="plain">Rendering of a key measles protein targeted by neutralizing human antibodies</media:title>
        <media:description type="plain">This rendering shows a key measles protein (white) targeted by neutralizing human antibodies (pink). Credit: Dawid Zyla, La Jolla Institute for Immunology</media:description>
      </media:content>
    </item>
    <item>
      <title>Abdakibart phase II graded, puts Avalo in HS upper class </title>
      <description>
        <![CDATA[Avalo Therapeutics Inc. may have designed in lead asset abdakibart, a drug for hidradenitis suppurativa (HS) that offers a novel mechanism of action, wide dosing interval, and more-than-satisfying outcomes on the Hidradenitis Suppurativa Clinical Response 75 endpoint, just what the doctor – and Wall Street – ordered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730861</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730861-abdakibart-phase-ii-graded-puts-avalo-in-hs-upper-class</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Armpit.webp?t=1778102194" type="image/jpeg" medium="image" fileSize="161790">
        <media:title type="plain">Hand held near armpit</media:title>
      </media:content>
    </item>
    <item>
      <title>Evotec and Almirall derm alliance yields development candidate</title>
      <description>
        <![CDATA[Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730882</guid>
      <pubDate>Tue, 05 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730882-evotec-and-almirall-derm-alliance-yields-development-candidate</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Dermatologic-skin-layer-molecules-drug.webp?t=1777994425" type="image/jpeg" medium="image" fileSize="407682">
        <media:title type="plain">Illustration showing skin anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>BLR Bio’s BLR-200 shows promise in systemic sclerosis models</title>
      <description>
        <![CDATA[BLR Bio LLC has presented new data highlighting the potential of BLR-200 for the treatment of systemic sclerosis (scleroderma). The company also presented data on its research on CCN proteins as potential noninvasive biomarkers for systemic sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730813</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730813-blr-bios-blr-200-shows-promise-in-systemic-sclerosis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Inflammatory/rheumatoid-arthritis-hand-pain.webp?t=1731947301" type="image/jpeg" medium="image" fileSize="561083">
        <media:title type="plain">Photo of older woman holding hand that's colored red</media:title>
      </media:content>
    </item>
    <item>
      <title>Dermatology specialist Leo Pharma makes a $50M move into gene therapy</title>
      <description>
        <![CDATA[Dermatology specialist Leo Pharma A/S is moving into gene therapy with the $50 million acquisition of Replay Holdings LLC, a seed-stage company that is developing high capacity herpes simplex virus vectors to treat rare inherited diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730748</guid>
      <pubDate>Thu, 30 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730748-dermatology-specialist-leo-pharma-makes-a-50m-move-into-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Skin-anatomy-and-DNA.webp?t=1777580724" type="image/jpeg" medium="image" fileSize="187452">
        <media:title type="plain">Skin anatomy and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Pharmability completes toxicology program for TIR-C</title>
      <description>
        <![CDATA[Pharmability AB (formerly Tirmed Pharma AB) has completed its GLP toxicology program for TIR-C, the company’s cutaneous drug candidate for atopic dermatitis, confirming a favorable safety profile.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730796</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730796-pharmability-completes-toxicology-program-for-tir-c</link>
    </item>
    <item>
      <title>Chiesi snags on-demand HAE drug in $1.9B Kalvista buy </title>
      <description>
        <![CDATA[In its largest acquisition to date, Chiesi Group is buying Kalvista Pharmaceuticals Inc. for $27 per share, a roughly 40% premium to the previous day’s closing price, putting the total deal value at about $1.9 billion. In return, the Italian pharma firm adds to its rare disease franchise Kalvista’s recently approved hereditary angioedema (HAE) drug, plasma kallikrein inhibitor Ekterly (sebetralstat), which has gotten off to a strong commercial launch as the only orally available, on-demand treatment for HAE.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730681</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730681-chiesi-snags-on-demand-hae-drug-in-19b-kalvista-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Ekterly.webp?t=1751908254" type="image/png" medium="image" fileSize="221805">
        <media:title type="plain">Ekterly pill and packaging</media:title>
        <media:description type="plain">Credit: Kalvista Pharmaceuticals Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>MANE event: Veradermics beats expectations in pattern hair loss trial</title>
      <description>
        <![CDATA[Shares of Veradermics Inc. spiked as the first top-line readout from its registrational program for VDPHL-01 showed the oral, extended-release version of minoxidil surpassed expectations in men with mild to moderate pattern hair loss, setting up commercial aspirations as a potential best-in-indication treatment option.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730639</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730639-mane-event-veradermics-beats-expectations-in-pattern-hair-loss-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Male-hair-loss.webp?t=1764799994" type="image/jpeg" medium="image" fileSize="1019229">
        <media:title type="plain">Male hair loss</media:title>
      </media:content>
    </item>
    <item>
      <title>Dupi whoopie: Sanofi/Regeneron cheered for sales, new approval</title>
      <description>
        <![CDATA[As Sanofi SA gets ready to welcome a new CEO, the company along with partner Regeneron Pharmaceuticals Inc. said a happy hello as well to robust sales of Dupixent (dupilumab, dupi) and gained U.S. FDA clearance for the IL-4 receptor alpha antagonist to treat children, ages 2 to 11, with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730601</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730601-dupi-whoopie-sanofi-regeneron-cheered-for-sales-new-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Dupixent.webp?t=1674851490" type="image/png" medium="image" fileSize="132469">
        <media:title type="plain">Dupixent </media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730574</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730574-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>Nektar’s rezpeg more than worth its SALT in alopecia phase IIb</title>
      <description>
        <![CDATA[With rezpegaldesleukin (rezpeg) phase IIb data in alopecia areata holding strong over time, backers of Nektar Therapeutics Inc. are hopeful that the biologic can do for the hair loss market what Dupixent (dupilumab, Regeneron Pharmaceuticals Inc./Sanofi SA) did in atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730481</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730481-nektars-rezpeg-more-than-worth-its-salt-in-alopecia-phase-iib</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Hair-loss-illustration2.webp?t=1776804334" type="image/jpeg" medium="image" fileSize="693160">
        <media:title type="plain">Hand showing bald patch of scalp</media:title>
      </media:content>
    </item>
    <item>
      <title>Daiichi to divest consumer health unit to Suntory for $1.5B</title>
      <description>
        <![CDATA[Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730407</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730407-daiichi-to-divest-consumer-health-unit-to-suntory-for-15b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Arrows-opposite-directions.webp?t=1588276411" type="image/png" medium="image" fileSize="20890">
        <media:title type="plain">Two arrows in opposite directions</media:title>
      </media:content>
    </item>
    <item>
      <title>US FDA cites first dispenser for violating Rx supply chain act </title>
      <description>
        <![CDATA[If a recent warning letter is anything to go by, the U.S. FDA could be using the 2013 Drug Supply Chain Security Act as another enforcement tool to shut down unauthorized suppliers by clamping down on the dispensers that purchase their unapproved drug products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730300</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730300-us-fda-cites-first-dispenser-for-violating-rx-supply-chain-act</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-sign.webp?t=1588870122" type="image/png" medium="image" fileSize="459620">
        <media:title type="plain">FDA sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal </title>
      <description>
        <![CDATA[Abbvie Inc. is buying exclusive rights to develop, manufacture and commercialize two Nav1.8 inhibitors for pain – HSK-55718 and HSK-51155 – from Haisco Pharmaceutical Group Co. Ltd. for $30 million up front and up to $715 million in milestone payments, plus royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730297</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Pain-med-illustration2.webp?t=1776187647" type="image/jpeg" medium="image" fileSize="427247">
        <media:title type="plain">Open capsule delivering pain relief to body</media:title>
      </media:content>
    </item>
    <item>
      <title>Biohaven’s BHV-1450 shows promise for pemphigus vulgaris</title>
      <description>
        <![CDATA[Pemphigus vulgaris (PV) is a life-threatening autoimmune disease affecting the skin, causing painful erosions on the skin and mucous membranes. PV is caused by IgG4 autoantibodies that target desmoglein 1 (DSG1) and DSG3, which are involved in keratinocyte cell-cell adhesion. There is a high unmet medical need for PV, since current therapies rely on systemic corticosteroids and immunosuppressants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730331</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730331-biohavens-bhv-1450-shows-promise-for-pemphigus-vulgaris</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/antibodies-lab-research.webp?t=1717686528" type="image/jpeg" medium="image" fileSize="266442">
        <media:title type="plain">Lab glassware and antibodies art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>DXP-006 reduces disease severity in psoriasis models</title>
      <description>
        <![CDATA[Researchers from Singlomics Zhuhai Danxu Biopharmaceuticals Co. Ltd. presented DXP-006, a humanized antibody targeting IL1RAP, a shared co-receptor required for IL-1, IL-33 and IL-36 cytokines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730258</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730258-dxp-006-reduces-disease-severity-in-psoriasis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Dermatology-skin-layer-doctor.webp?t=1732551251" type="image/jpeg" medium="image" fileSize="478968">
        <media:title type="plain">Doctor holding illustration of cross section of skin</media:title>
      </media:content>
    </item>
    <item>
      <title>Topical ASO restores WRN function for chronic skin ulcers in Werner syndrome</title>
      <description>
        <![CDATA[Werner syndrome results from biallelic mutations in the WRN gene on chromosome 8, leading to accelerated aging symptoms. Researchers at Sumitomo Pharma Co. Ltd. have reported the development and characterization of WRN-108, a splice-switching antisense oligonucleotide (ASO) designed to induce exon 27 skipping in WRN transcripts carrying the c.3139-1G>C mutation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730187</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730187-topical-aso-restores-wrn-function-for-chronic-skin-ulcers-in-werner-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Genetic-mutation-illustration.webp?t=1759498851" type="image/png" medium="image" fileSize="448572">
        <media:title type="plain">Missing puzzle piece and broken DNA chain</media:title>
      </media:content>
    </item>
    <item>
      <title>Nrf2 activator counteracts atopic dermatitis pathology</title>
      <description>
        <![CDATA[Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with increased oxidative stress. In this context, pharmacological activation of the Keap1-Nrf2 pathway, a key regulator of antioxidant and cytoprotective gene expression, has emerged as a promising therapeutic strategy to re-establish redox homeostasis and reduce inflammation in AD. Researchers from the Korea Institute of Science and Technology reported the design and preclinical characterization of a novel Nrf2 activator in models of AD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730168</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730168-nrf2-activator-counteracts-atopic-dermatitis-pathology</link>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis</title>
      <description>
        <![CDATA[Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730042</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730042-infinimmune-presents-preclinical-data-on-anti-il-22-antibody-for-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/Antibodies-blue-orange-close-up.webp?t=1774969563" type="image/jpeg" medium="image" fileSize="944048">
        <media:title type="plain">3D illustration of antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>HXN-1023 drives robust anti-inflammatory responses in atopic dermatitis models</title>
      <description>
        <![CDATA[Dysregulated type 2 immune responses are central in atopic dermatitis (AD) pathophysiology. Key cytokine IL-13 drives epidermal barrier dysfunction and inflammation, while IL-31 mediates pruritus via activation of sensory neurons. Both represent clinically validated, complementary targets addressing both inflammation and itch in AD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730040</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730040-hxn-1023-drives-robust-anti-inflammatory-responses-in-atopic-dermatitis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/dermatologic-skin-layer-regenerative.webp?t=1745258161" type="image/jpeg" medium="image" fileSize="334698">
        <media:title type="plain">Skin, tissue layer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NAV-242 bispecific antibody supports quarterly dosing in HS</title>
      <description>
        <![CDATA[Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by dysregulated T-cell-mediated immune responses and suboptimal outcomes with current therapies. Increased expression of OX40 and OX40L in lesional HS skin suggests a contributory role for this pathway in disease-associated inflammation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730036</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730036-nav-242-bispecific-antibody-supports-quarterly-dosing-in-hs</link>
    </item>
    <item>
      <title>AAD 2026: Targeted oral therapies challenge injected biologics</title>
      <description>
        <![CDATA[Data presented at the 2026 American Academy of Dermatology (AAD) meeting have put the spotlight on the arrival of target-selective oral therapies that are set to challenge injected biologics in terms of efficacy, while offering greater convenience and improving access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729951</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729951-aad-2026-targeted-oral-therapies-challenge-injected-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>Multibody TEV‘325 achieves preclinical milestone</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease]]>
      </description>
      <guid>http://www.bioworld.com/articles/729930</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/collaboration-research-milestones-illustration.webp?t=1735313933" type="image/jpeg" medium="image" fileSize="78720">
        <media:title type="plain">Illustration of a road with three destination markers</media:title>
      </media:content>
    </item>
  </channel>
</rss>
